This article is more than 5 years old. Information may no longer be current.
CAT terminates glaucoma drug development after disappointing results
Click Here to Manage Email Alerts
CAMBRIDGE, England — A drug in clinical trials to improve the outcome of glaucoma surgery has failed to meet its primary endpoint, and as a result further development has been terminated, said developer Cambridge Antibody Technology in a press release.
Trabio (lerdelimumab, CAT-152) is a fully human monoclonal antibody that neutralizes transforming growth factor beta 2, a protein produced in response to injury in the eye, said CAT in the release. The protein has been linked to excessive scar tissue formation, a leading cause of glaucoma surgery failure.
According to the release, results from early clinical trials indicated a lower pressure in the eye and a trend toward reduced postop intervention in patients given Trabio.
For the second pivotal international trial, the endpoint was defined as the proportion of patients achieving an IOP between 6 and 16 mm Hg without use of additional glaucoma medications at months 6 and 12.
CAT had announced results of its first pivotal trial of Trabio in November; the drug had failed to improve the outcome of glaucoma surgery when compared with placebo.